Climb Bio (CLYM) Total Current Liabilities (2020 - 2026)
Climb Bio's (CLYM) quarterly Total Current Liabilities came in at $4.1 million in Q1 2026, down 42.14% YoY from $7.0 million in Q1 2025, and down 41.71% on a QoQ basis from $7.0 million in Q4 2025.
Climb Bio (CLYM) Total Current Liabilities (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Total Current Liabilities data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Total Current Liabilities fell 42.14% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 42.14% YoY) and the FY2025 annual result came in at $7.0 million, up 41.63% from the prior year.
- Total Current Liabilities retreated to $4.1 million in Q1 2026, from $7.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $7.6 million in Q2 2022 to a low of $2.8 million in Q4 2023.
- A 5-year average of $5.0 million and a median of $4.9 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 53.81% — and 2025, when it surged 138.51%.
- Tracing CLYM's Total Current Liabilities over 5 years: stood at $6.1 million in 2022, then tumbled by 53.53% to $2.8 million in 2023, then soared by 74.06% to $4.9 million in 2024, then jumped by 41.63% to $7.0 million in 2025, then slumped by 41.71% to $4.1 million in 2026.
- The last three Total Current Liabilities figures came in at $4.1 million (Q1 2026), $7.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 5.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.93 Mn |
| Mar 31, 2026 | 4.07 Mn |
| Dec 31, 2025 | 6.98 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Jun 30, 2025 | 6.21 Mn |
| Mar 31, 2025 | 7.04 Mn |
| Dec 31, 2024 | 4.93 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 2.83 Mn |
| Sep 30, 2023 | 2.90 Mn |
| Jun 30, 2023 | 3.62 Mn |
| Mar 31, 2023 | 4.92 Mn |
| Dec 31, 2022 | 6.10 Mn |
| Sep 30, 2022 | 6.28 Mn |
| Jun 30, 2022 | 7.61 Mn |
| Mar 31, 2022 | 6.90 Mn |
| Dec 31, 2021 | 6.03 Mn |
| Sep 30, 2021 | 5.59 Mn |